ArticleSensors (Basel, Switzerland)2018
Development of a Label-Free Immunosensor for Clusterin Detection as an Alzheimer's Biomarker.
Article in Sensors (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 40 citations in OpenAlex.
- Hybrid g-C₃N₄/ZnO nanocomposites for enhanced electrochemical detection of dengue virus serotype 2 (DENV2) NS1 protein biomarker.Mikrochimica acta · 2025Article
- An immobilized antibody-based affinity grid strategy for on-grid purification of target proteins enables high-resolution cryo-EM.Communications biology · 2024Article
- Article
- Revolutionizing the Early Detection of Alzheimer's Disease through Non-Invasive Biomarkers: The Role of Artificial Intelligence and Deep Learning.Sensors (Basel, Switzerland) · 2023Review
- Graphene FET Sensors for Alzheimer's Disease Protein Biomarker Clusterin Detection.Frontiers in molecular biosciences · 2021Article
- Novel Trends in Electrochemical Biosensors for Early Diagnosis of Alzheimer's Disease.International journal of analytical chemistry · 2021Review
- A label-free biosensor based on graphene and reduced graphene oxide dual-layer for electrochemical determination of beta-amyloid biomarkers.Mikrochimica acta · 2020Article
- Emphasis Learning, Features Repetition in Width Instead of Length to Improve Classification Performance: Case Study-Alzheimer's Disease Diagnosis.Sensors (Basel, Switzerland) · 2020Article
- Article
- Early Detection of Alzheimer's Disease Based on Clinical Trials, Three-Dimensional Imaging Data, and Personal Information Using Autoencoders.Journal of medical signals and sensorsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clusterin (CLU) has been associated with the clinical progression of Alzheimer's disease (AD) and described as a potential AD biomarker in blood plasma. Due to the enormous attention given to cerebrospinal fluid (CSF) biomarkers for the past couple of decades, recently found blood-based AD biomarkers like CLU have not yet been reported for biosensors. Herein, we report the electrochemical detection of CLU for the first time using a screen-printed carbon electrode (SPCE) modified with 1-pyrenebutyric acid
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.